KRAS and cancer: Indeed, WEE1 has been shown to be a key dependency in KRAS-mutant cancers (20, 21, 31–34), and co-inhibition of KRAS with WEE1 and other cell-cycle and mitotic proteins has been identified as promising combination strategies through large-scale screening efforts (32, 35, 36).